Perioperative Management of Direct Oral Anticoagulants (DOACs) in Elective Surgery Candidates: A Drug Utilization Evaluation (DUE) Study
-
Negar Kariznoee
,
Reza Mollazadeh
,
Soha Namazi
,
Shakila Yaribash
,
Ramin Ansari
,
Keyhan Mohammadi
Abstract
Background: This study aimed to evaluate physicians' practice regarding perioperative Direct Oral Anticoagulants (DOACs) management in patients undergoing elective procedures and compare it to established institutional standard protocols and the most recent guidelines.
Methods: Over seven months, a cross-sectional descriptive-analytical study was conducted at Imam Khomeini Hospital Complex, affiliated with Tehran University of Medical Sciences. Patients receiving DOACs and undergoing elective procedures/surgery were enrolled.
Results: In total, 170 patients who underwent 200 procedures while taking DOACs were included, with a total mean age (SD) of 62.2 (16.5) years. DOAC therapy was primarily prescribed for atrial fibrillation (75%) and deep vein thrombosis (25%), with 97% taking Apixaban. Approximately 125 (62.5%) of the performed procedures were categorized as high risk for bleeding, among which only 16.8% adhered to preoperative management guidelines. The mean (SD) time to reintroduce DOACs after procedures was 57.7 (45.3) hours. Bridge therapy was used in 66% of cases before and 74% after procedures. Blood products were administered in 36 cases of high-risk procedures. The average overall perioperative management score calculated was 3.3, representing less than 50% of the maximum possible score of 7. In only 8.5% (N=17) of the procedures, the total pre- and postoperative management of DOACs was concordant with the guideline.
Conclusion: The study showed poor perioperative adherence to international DOAC management guidelines. Expert collaboration is crucial for DOAC patients undergoing surgery. More research is needed to understand the reasons for low adherence.
Kotalczyk A, Lip GY, Calkins H. The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2021;10(2):65-67.
Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the Practical Management of the Direct Oral Anticoagulants (DOACs) in VTE Treatment. J Thromb Thrombolysis. 2016;41:206-232.
Vakili Z, Heydarpour F, Shahbazi F. Survey of Knowledge and Attitude of Pharmacists about Direct Oral Anticoagulants: A Cross-Sectional Study. J Pharm Care. 2021;9(3):114-118.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-analysis of Randomized Trials. The Lancet. 2014;383(9921):955-962.
Steffel J, Braunwald E. Novel Oral Anticoagulants: Focus on Stroke Prevention and Treatment of Venous Thrombo-embolism. Eur Heart J. 2011;32(16):1968-1976.
Chen A, Stecker E, A. Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020;9(13):e017559.
Wiggins BS, Dixon DL, Neyens RR, Page RL, Gluckman TJ. Select Drug-drug Interactions with Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341-1350.
Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612-1676.
Zathar Z, Karunatilleke A, Fawzy AM, Lip GYH. Atrial Fibrillation in Older People: Concepts and Controversies. Front Med. 2019;6:175.
Colacci M, Tseng EK, Sacks CA, Fralick M. Oral Anticoagulant Utilization in the United States and United Kingdom. J Gen Intern Med. 2020;35(8):2505-2507.
Mohammadi K, Ansari R, Yaribash S. Hypersensitivity Reaction to Rivaroxaban with a Successful Switch to Apixaban: A Case Report. Clin Case Rep. 2024;12(8):e9213.
Omling E, Jarnheimer A, Rose J, Björk J, Meara J, Hagander L. Population-based Incidence Rate of Inpatient and Outpatient Surgical Procedures in a High-income Country. Br J Surg. 2018;105(1):86-95.
Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International Trends in Clinical Characteristics and Oral Anticoagulation Treatment for Patients with Atrial Fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II Registries. Am Heart J. 2017;194:132-140.
Proietti M, Laroche C, Opolski G, Maggioni AP, Boriani G, Lip GY, et al. ‘Real-world’atrial Fibrillation Management in Europe: Observations from the 2-year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace. 2017;19(5):722-733.
Williams BA, Honushefsky AM, Berger PB. Temporal Trends in the Incidence, Prevalence, and Survival of Patients with Atrial Fibrillation from 2004 to 2016. Am J Cardiol. 2017;120(11):1961-1965.
Terrier J, Mach A, Fontana P, Bonhomme F, Casini A. Clinicians' adherence to Guidelines for the Preoperative Management of Direct Oral Anticoagulants in a Tertiary Hospital: A Retrospective Study. BMC Anesthesiol. 2023;23(1):314.
Douketis JD. Perioperative Anticoagulation Management in Patients who are Receiving Oral Anticoagulant Therapy: A Practical Guide for Clinicians. Thromb Res. 2002;108(1):3-13.
Tafur A, Douketis J. Perioperative Management of Anticoagulant and Antiplatelet Therapy. Heart. 2018;104(17):1461-1467.
Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243.
Stoellberger C, Finsterer J. Update on Drug Interactions with Non-vitamin-K-antagonist Oral Anticoagulants for Stroke Prevention in Elderly Patients. Expert Rev Clin Pharmacol. 2021;14(5):569-581.
Li A, Li MK, Crowther M, Vazquez SR. Drug-drug Interactions with Direct Oral Anticoagulants Associated with Adverse Events in the Real World: A Systematic Review. Thromb Res. 2020;194:240-245.
Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients with Liver Disease. J Am Coll Cardiol. 2018;71(19):2162-2175.
Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017;117(12):2415-2424.
Vazin A, Azadi S, Jalali A, Karimzadeh I, Borhani-Haghighi A, Safari A, et al. Drug Utilization Evaluation of Rivaroxaban in both Inpatient and Outpatient Settings: Using Standard Guidelines. Trends Pharmacol Sci. 2022;8(4):253-262.
Niloufar Sadat M, Mehrnoush D, Alireza H, Rasool S, Azadeh K, Sepehr B. Evaluation of the Adherence to the Antimicrobial Prophylaxis Guidelines before Cardiac Surgeries in a Specialized University Hospital: A Unicenter Cross-Sectional Study from Iran. J Pharm Care. 2023;11(4):214-218.
Lupi SM, Baena ARy, editors. Patients Taking Direct Oral Anticoagulants (DOAC) Undergoing Oral Surgery: A Review of the Literature and a Proposal of a Peri-operative Management Protocol. Healthcare (Basel). 2020;8(3):281.
Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, et al. Use and Outcomes Associated with Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131(5):488-494.
Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373(9):823-833.
Terrier J, Mach A, Fontana P, Bonhomme F, Casini A. Clinicians’ adherence to Guidelines for the Preoperative Management of Direct Oral Anticoagulants in a Tertiary Hospital: A Retrospective Study. BMC Anesthesiol. 2023;23(1):314.
Khalili H, Dashti-Khavidaki S, Talasaz AH-H, Najmedin F, Hosseinpoor R. Anticoagulant Utilization Evaluation in a Teaching Hospital: A Prospective Study. J Pharm Pract. 2010;23(6):579-584.
Fahimi F, Bani AS, Behzad NN, Ghazi TL. Enoxaparin Utilization Evaluation: An Observational Prospective Study in Medical Inpatients. Iran J Pharm Res. 2008;7(1):77-82.
Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019;179(11):1469-1478.
Baiardini I, Braido F, Bonini M, Compalati E, Canonica GW. Why do Doctors and Patients not Follow Guidelines? Curr Opin Allergy Clin Immunol. 2009;9(3):228-233.
| Files | ||
| Issue | Vol 13, No 1 (Winter 2025) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v13i1.18402 | |
| Keywords | ||
| Direct oral anticoagulant Surgery Atrial fibrillation Deep vein thrombosis DUE Drug Utilization Evaluation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
